iX Biopharma is a listed, specialty pharmaceutical and nutraceutical company focusing on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery. iX Biopharma’s pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharma’s drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia. iX Biopharma has developed Xativa, the world’s first freeze-dried sublingual medicinal cannabis wafer. The Group’s nutraceuticals division, Entity Health Limited, is engaged in the development and commercialisation of nutraceutical products. Subsidiaries: iX Syrinx ( https://www.ixsyrinx.com ) Entity health ( https://www.entity-health.com )